Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy

• Published in: Clinical pharmacology: advances and applications 2019-01, Vol.11, p.15-23
• Main Authors: North, William G, Liu, Fuli, Dragnev, Konstantin H, Demidenko, Eugene
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Cancer therapies; Chemotherapy; combination therapy; inhibitors; Lung cancer; Medicine; NMDA receptors; Original Research; Ovarian cancer; Post traumatic stress disorder; Proteins; small-cell lung cancer; Tumors
• ISSN: 1179-1438; 1179-1438
• DOI: 10.2147/CPAA.S183885

Small-cell lung cancer (SCLC) has a poor prognosis since there is currently no effective therapy for commonly recurring disease. In our previous study, both primary and recurrent human tumors have been shown to express functional -methyl-D-aspartate (NMDA) receptors, and blockade of these receptors with GluN1 and GluN2B antagonists decreased tumor cell viability in vitro, and growth of tumor xenografts in nu/nu mice. In this study, we examine the influence of the GluN2B antagonist ifenprodil and the channel-blocker antagonist memantine, on cell viability and growth of tumor xenografts of recurrent SCLC (rSCLC) in mice. Both antagonists significantly reduced cell viability and levels of components of the ERK1/2 pathway, increased apoptosis, and at very safe levels significantly reduced the growth of tumors in mice. Each antagonist and topotecan had additive effects to reduce cell viability with significant synergy demonstrated for the case of memantine. More significantly, combination treatments of xenografts in mice with ifenprodil and the chemotherapeutic agent topotecan produced clear additive effects that completely stopped tumor growth. Moreover, the ifenprodil and topotecan combination showed excellent supra-addition or synergy of inhibition for tumors ≤300 mm in size ( =4.7E-4). Combination treatment of memantine with topotecan also showed clear addition but, unlike ifenprodil, no synergy for the doses chosen. Since topotecan is a drug of choice for treatment of rSCLC, our findings suggest that combining this agent with NMDA receptor blockade using the GluN2B antagonist, ifenprodil, will significantly improve patient outcomes.